175 related articles for article (PubMed ID: 27363386)
1. PSMA-Targeted
Gorin MA; Rowe SP; Hooper JE; Kates M; Hammers HJ; Szabo Z; Pomper MG; Allaf ME
Eur Urol; 2017 Jan; 71(1):145-146. PubMed ID: 27363386
[No Abstract] [Full Text] [Related]
2. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
3. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
[TBL] [Abstract][Full Text] [Related]
4. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted
Meyer AR; Carducci MA; Denmeade SR; Markowski MC; Pomper MG; Pierorazio PM; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2019 Aug; 33(8):617-623. PubMed ID: 31147927
[TBL] [Abstract][Full Text] [Related]
5. Correlation of PSMA-Targeted
Tosoian JJ; Gorin MA; Rowe SP; Andreas D; Szabo Z; Pienta KJ; Pomper MG; Lotan TL; Ross AE
Clin Genitourin Cancer; 2017 Feb; 15(1):e65-e68. PubMed ID: 27751686
[No Abstract] [Full Text] [Related]
6. Semiquantitative Parameters in PSMA-Targeted PET Imaging with
Li X; Rowe SP; Leal JP; Gorin MA; Allaf ME; Ross AE; Pienta KJ; Lodge MA; Pomper MG
J Nucl Med; 2017 Jun; 58(6):942-946. PubMed ID: 27932557
[No Abstract] [Full Text] [Related]
7. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
[TBL] [Abstract][Full Text] [Related]
8. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
[TBL] [Abstract][Full Text] [Related]
9. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
10. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP
Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341
[TBL] [Abstract][Full Text] [Related]
11. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Sahakyan K; Li X; Lodge MA; Werner RA; Bundschuh RA; Bundschuh L; Kulkarni HR; Schuchardt C; Baum RP; Pienta KJ; Pomper MG; Ross AE; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):181-189. PubMed ID: 31115751
[TBL] [Abstract][Full Text] [Related]
12. PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?
Rowe SP; Mana-Ay M; Javadi MS; Szabo Z; Leal JP; Pomper MG; Pienta KJ; Ross AE; Gorin MA
Clin Genitourin Cancer; 2016 Feb; 14(1):e115-8. PubMed ID: 26603549
[No Abstract] [Full Text] [Related]
13. Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease.
Rhee H; Ng KL; Tse BW; Yeh MC; Russell PJ; Nelson C; Thomas P; Samaratunga H; Vela I; Gobe G; Wood S
Pathology; 2016 Oct; 48(6):613-6. PubMed ID: 27567227
[No Abstract] [Full Text] [Related]
14. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere C; Bassanelli M; Ceribelli A; Rasul S; Li S; Prior JO; Cicone F
Curr Urol Rep; 2019 Oct; 20(11):68. PubMed ID: 31605269
[TBL] [Abstract][Full Text] [Related]
15. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
16. Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.
Gomez E; Tran PT; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
Clin Nucl Med; 2019 Apr; 44(4):e313-e314. PubMed ID: 30789396
[TBL] [Abstract][Full Text] [Related]
17. Low levels of PSMA expression limit the utility of
Campbell SP; Baras AS; Ball MW; Kates M; Hahn NM; Bivalacqua TJ; Johnson MH; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2018 Jan; 32(1):69-74. PubMed ID: 29067547
[TBL] [Abstract][Full Text] [Related]
18. Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
Endepols H; Morgenroth A; Zlatopolskiy BD; Krapf P; Zischler J; Richarz R; Muñoz Vásquez S; Neumaier B; Mottaghy FM
BMC Cancer; 2019 Jun; 19(1):633. PubMed ID: 31242896
[TBL] [Abstract][Full Text] [Related]
19. An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Chu LC; Pienta KJ; Pomper MG; Ross AE; Macura KJ
Clin Nucl Med; 2017 Oct; 42(10):e441-e443. PubMed ID: 28806262
[TBL] [Abstract][Full Text] [Related]
20. Clear cell renal cell carcinoma with high PSMA uptake.
Yepes MM; Herrera Ortiz AF; Del Castillo V; Rojas J
BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38663894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
